Request Appointment
160 East 53rd StreetNew York, NY 10022
Overview of Dr. Yaeger
Dr. Rona Yaeger is an oncologist in New York, NY and is affiliated with Memorial Sloan-Kettering Cancer Center. She received her medical degree from NYU School of Medicine and has been in practice 14 years. She specializes in medical oncology.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2003 - 2006
New York University School of MedicineClass of 2003
Certifications & Licensure
FL State Medical License 2021 - Present
NY State Medical License 2004 - 2026
NJ State Medical License 2020 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Start of enrollment: 2013 Jan 01
- This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours) Start of enrollment: 2018 Aug 08
Publications & Presentations
PubMed
- Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations.Michelangelo Marasco, Dinesh Kumar, Santiago Garcia Borrego, Tessa Seale, Giulia Maddalena
Cancer Discovery. 2025-04-28 - Nonoperative Management of Mismatch Repair-Deficient Tumors.Andrea Cercek, Michael B Foote, Benoit Rousseau, J Joshua Smith, Jinru Shia
The New England Journal of Medicine. 2025-04-27 - Clinical Outcomes, Patterns of Failure, and Salvage Therapies of a Large Modern Cohort of Patients With Anal Squamous Cell Carcinoma Treated With Definitive-Intent Int...Diana A Roth O'Brien, Vasilis C Hristidis, Zakaria Chakrani, Patrick McCann, Antonio Damato
International Journal of Radiation Oncology, Biology, Physics. 2025-03-15
Press Mentions
Potential New Treatment for KRAS-GI2D Lung Cancer Reported in First-of-Its-Kind Clinical TrialApril 27th, 2025- Two Positive Trials and a Breakthrough Therapy Designation for KRAS InhibitorsDecember 22nd, 2022
- Stress Response Protein Links Inflammatory Disease to Colon CancerFebruary 19th, 2021
- Join now to see all
Grant Support
- Neoadjuvant Tucatinib plus Trastuzumab in HER2-amplified Locally Advanced Rectal CancerSLOAN-KETTERING INST CAN RESEARCH2024–2029
- Targeting Chromosomal Instability in the Evolution of Resistance to Matched Therapies Against Colorectal Cancer to Extend Treatment ResponseSLOAN-KETTERING INST CAN RESEARCH2025–2027
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
